 This is an open-label, multicentre, 2-arm randomised phase II trial of gemcitabinecarboplatin Apatorsen OGX-427 versus gemcitabinecarboplatin alone in patients with previously untreated advanced squamous cell lung cancers. Patients will be randomised 1:1 to one of the two treatment arms: 